Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

[1]  A. Drilon,et al.  Selective RET kinase inhibition for patients with RET-altered cancers , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Drilon,et al.  Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes , 2018, Nature Reviews Clinical Oncology.

[3]  A. Ravaud,et al.  Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study. , 2017, European journal of cancer.

[4]  Jing Wang,et al.  The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[5]  J. Ngeow,et al.  Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review. , 2016, The oncologist.

[6]  J. Larkin,et al.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. , 2015, The Lancet. Oncology.

[7]  R. Larson,et al.  Next generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma , 2015, Leukemia.

[8]  G. Sica,et al.  A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[9]  W. Pao,et al.  Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.

[10]  A. Shaw,et al.  Molecular Pathways Molecular Pathways : Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies , 2014 .

[11]  S. Gabriel,et al.  Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.

[12]  L. Mulligan.  RET revisited: expanding the oncogenic portfolio , 2014, Nature Reviews Cancer.

[13]  Razelle Kurzrock,et al.  Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. , 2014, Cell reports.

[14]  J. Fagin,et al.  Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. , 2013, Endocrine-related cancer.

[15]  C. Nathan,et al.  Dual PI3K/mTOR Inhibitors: Does p53 Modulate Response? , 2013, Clinical Cancer Research.

[16]  James H. Doroshow,et al.  Safety and feasibility of targeted agent combinations in solid tumours , 2013, Nature Reviews Clinical Oncology.

[17]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[18]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Wei Zhang,et al.  Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer , 2011, Clinical Cancer Research.

[20]  R. Herbst,et al.  Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. , 2011, The Journal of clinical investigation.

[21]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[22]  G. Tortora,et al.  Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs , 2008, British Journal of Cancer.

[23]  P. Smolewski.  Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway , 2006, Anti-cancer drugs.

[24]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[25]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[26]  H. Hurwitz,et al.  Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[28]  G. Fontanini,et al.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. , 2002, Cancer research.

[29]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[30]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[31]  S. Ou,et al.  Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. , 2018, Cancer discovery.

[32]  L. Paz-Ares,et al.  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.